Assuntos
Anticorpos Monoclonais/efeitos adversos , Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Infliximab , Masculino , Pessoa de Meia-Idade , Proteínas de Neoplasias/efeitos adversos , Receptores Tipo II do Fator de Necrose Tumoral , Espondilite Anquilosante/tratamento farmacológico , Receptores Chamariz do Fator de Necrose TumoralRESUMO
A characteristic manifestation of SAPHO syndrome is hyperostosis, which most typically affects the sternoclavicular joints. Two cases of SAPHO syndrome with painful hyperostosis of the femur are reported. This misleading localization can lead to delays in the diagnosis and treatment.
Assuntos
Fêmur , Hiperostose/complicações , Osteíte/complicações , Psoríase/complicações , Sinovite/complicações , Adulto , Antirreumáticos/uso terapêutico , Difosfonatos/uso terapêutico , Feminino , Fêmur/diagnóstico por imagem , Fêmur/fisiopatologia , Humanos , Hiperostose/diagnóstico , Hiperostose/fisiopatologia , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Dor , Pamidronato , Radiografia , Cintilografia , Sulfassalazina/uso terapêutico , SíndromeRESUMO
Twenty patients with classical or proved rheumatoid arthritis were treated with Isoprinosine. 13 patients received a dose of 25 mg/kg/day and 7 received a dose of 50 mg/kg/day, continuously for 2 months and then discontinuously, 5 days every fortnight. The series being treated with 25 mg/kg/day (7 patients) have received treatment for 12 months. No side effects have been observed; the only reason for ceasing treatment was its ineffectiveness (after at least 3 months of administration). The dosage of the associated anti-inflammatory drugs did not need to be increased, but neither was it decreased. The authors conclude that Isoprinosine is largely ineffective clinically, on laboratory tests and in terms of immunology, at least with the therapeutic protocols tested here.